Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.74 |
| ▸ | ACACA | Q13085 | 14/20 | 0.74 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.50 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465253 | 1.00 | ACACB (0.74) | ACACBACACAKDM2BGAAMBTD1 | |
| SCHEMBL6183530 | 0.94 | ACACB (0.66) | ACACBACACAKDM2BGAA | |
| SCHEMBL27596430 | 0.93 | ACACB (0.69) | ACACBACACAMBTD1TP53BP1L3MBTL3 | |
| Diethylamine SCHEMBL7108528 | 0.92 | ACACB (0.71) | ACACBACACAKDM2B | |
| SCHEMBL2622327 | 0.90 | ACACB (0.74) | ACACBACACAKDM2BGAAMBTD1 | |
| SCHEMBL13953186 | 0.90 | ACACB (0.72) | ACACBACACAKDM2BGAA | |
| SCHEMBL6182395 | 0.90 | ACACB (0.72) | ACACBACACAKDM2BGAA | |
| SCHEMBL6183505 | 0.89 | ACACB (0.84) | ACACBACACAKDM2BGAAMBTD1 | |
| SCHEMBL2622325 | 0.88 | ACACB (0.83) | ACACBACACAKDM2BMBTD1TP53BP1 | |
| SCHEMBL976349 | 0.88 | ACACB (0.83) | ACACBACACAKDM2BMBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | claimed |
| EP-2581081-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-04-17 | — | — | EP | claimed |
| EP-2572712-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-27 | — | — | EP | claimed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2581081-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2572712-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-27 | — | — | EP | disclosed |
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1478437-A1 | ACC INHIBITORS | Pfizer Products Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003072197-A1 | ACC INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | ACACB 312/4885ACACA 702/4885KDM2B 3004/4885 |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885KDM2B 4022/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | ACACB 949/4885ACACA 1144/4885KDM2B 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.